Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

Similar presentations


Presentation on theme: "Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV."— Presentation transcript:

1 Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV Carrat F, et. al. JAMA. 2004;292:2839-48.

2 Hepatitis web study Peginterferon + RBV versus Interferon + RBV in HCV & HIV RIBAVIC Study: Design Study - Randomized, phase 3, open-label, parallel group trial - Conducted at 71 French centers Subjects - N = 412 chronically infected with both HCV and HIV - Treatment naïve; 48% genotype 1 - CD4 >200 cells/mm 3 Regimens (48 Week Treatment) - Peginterferon alfa-2b 1.5 µg 1x/week + Ribavirin 800 mg/day - Interferon alfa-2b: 3 million IU 3x/week + Ribavirin 800 mg/day Primary Endpoint - Undetectable serum HCV RNA 24 weeks after stopping treatment Source: Carrat F, et. al. JAMA. 2004;292:2839-48.

3 Hepatitis web study Peginterferon alfa-2b + Ribavirin Interferon alfa-2b + Ribavirin 48720 Week Source: Carrat F, et. al. JAMA. 2004;292:2839-48. Peginterferon + RBV versus Interferon + RBV in HCV & HIV RIBAVIC Study: Design Drug Dosing Peginterferon alfa-2b: 1.5 µg/kg 1x/week Standard Interferon alfa-2b 3 million units 3x/week Ribavirin (divided bid): 800 mg/day SVR24 N = 205 N = 207

4 Hepatitis web study Peginterferon + RBV versus Interferon + RBV in HCV & HIV RIBAVIC Study: Design RIBAVIC Study: SVR24 by Treatment Regimen and Genotype Source: Carrat F, et. al. JAMA. 2004;292:2839-48. 41/20756/2058/12921/12533/7635/80 P =.047 P =.006 P =.88

5 Hepatitis web study Source: Carrat F, et. al. JAMA. 2004;292:2839-48. Peginterferon + RBV versus Interferon + RBV in HCV & HIV RIBAVIC Study: Conclusions Conclusion: “In combination with ribavirin, treatment with peginterferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients.”

6 Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.


Download ppt "Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV."

Similar presentations


Ads by Google